NVSEF - PepGen: Moving To Hold Rating On Best Mean Splicing Correction In DM1 Testing
2025-10-29 17:50:28 ET
The last time I wrote about PepGen ( PEPG ) it was with respect to a Seeking Alpha article entitled " PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope of Current Treatments ". With respect to this article, I spoke about the potential it had in advancing PGN-EDO51 for the treatment of patients with Duchenne Muscular Dystrophy [DMD] amenable to exon 51 skipping. There was an initial proof-of-concept, which was highly encouraging and I went over such data in that article. Unfortunately, the latest update is that the company chose to terminate further development of this program and the reason why is because it failed to see a significant amount of dystrophin being produced. The end result was that the 10 mg/kg of PGN-EDO51 was able to increase total dystrophin by 0.59% of normal levels [an average increase of 0.36%]....
PepGen: Moving To "Hold" Rating On Best Mean Splicing Correction In DM1 Testing